Treatment of Breast Cancer with 5-Fluorouracil
Authors: HORACE K. IVY
Journal: Annals of Internal Medicine (1962)

Article1 October 1962Treatment of Breast Cancer with 5-FluorouracilHORACE K. IVY, M.D.HORACE K. IVY, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-57-4-598 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe role of 5-fluorouracil in the chemotherapy of breast cancer has yet to be accurately defined. That it is useful and effective in some cases is beyond doubt, but its associated toxicity renders it a formidable agent to use.For some years, metabolic differences between normal and neoplastic tissues have been sought with the hope that such differences could be exploited by chemotherapeutic agents. Both Rutman (1) and Heidelberger (2), with their co-workers, have observed that uracil may be preferentially utilized for synthesis of nucleic acid in certain neoplastic tissues. Consequently, several altered molecules of uracil were synthesized and their...References1. RUTMANCANTAROWPASCHKIS RJAKE: Studies in 2-acetylamino-fluorene carcinogenesis. III. The utilization of uracil-2-C14 by preneoplastic rat liver and rat hepatoma. Cancer Res. 14: 119, 1954. MedlineGoogle Scholar2. HEIDELBERGERLEIBMANHARBERSBHARGAVA CKCEPM: The comparative utilization of uracil-2-C14 by liver, intestinal mucosa, and flexner-jobling carcinoma in the rat. Cancer Res. 17: 399, 1957. MedlineGoogle Scholar3. HAKALALAWWELCH MTLWAD: Inhibitory activity of 6-azauracil, 6-uracil methyl sulfone, and related compounds on the growth of mouse lymphomas and sarcoma 180. Amer. Ass. Cancer Res. Proc. 2: 113, 1956. Google Scholar4. DUSCHINSKYPLEVENHEIDELBERGER REC: The synthesis of 5-fluoropyrimidines. Amer. Chem. Soc. J. 79: 4559, 1957. CrossrefGoogle Scholar5. HEIDELBERGERCHAUDHURIDANNEBERGMOORENGRIESBACHDUSCHINSKYSCHNITZERPLEVENSCHEINER CNKPDLRRJEJ: Fluorinated pyrimidines, a new class of tumor-inhibitory compounds. Nature (Lond.) 179: 663, 1957. CrossrefMedlineGoogle Scholar6. COHENFLAKSBARNERLOEBLICHTENSTEIN SSJGHDMRJ: The mode of action of 5-fluorouracil and its derivatives. Nat. Acad. Sci. Proc. 44: 1004, 1958. CrossrefMedlineGoogle Scholar7. ANSFIELDCURRERI FJAR: Further clinical studies with 5-fluorouracil. Nat. Cancer Inst. J. 22: 497, 1959. MedlineGoogle Scholar8. HURLEYELLISONRIESCHSCHULTE JDEHJW: Chemotherapy of solid carcinoma. JAMA 174: 1696, 1960. CrossrefMedlineGoogle Scholar9. VAITKEVICIUSBRENNANBECKETTKELLYTALLEY VKMJVLJERW: Clinical evaluation of cancer chemotherapy with 5-fluorouracil. Cancer 14: 131, 1961. CrossrefMedlineGoogle Scholar10. KENNEDYTHEOLOGIDES BJA: The role of 5-fluorouracil in malignant disease. Ann. Intern. Med. 55: 719, 1961. LinkGoogle Scholar11. WEISSJACKSONCARABASI AJLGR: An evaluation of 5-fluorouracil in malignant disease. Ann. Intern. Med. 55: 731, 1961. LinkGoogle Scholar12. YOUNGELLISONSULLIVANLEVICKKAUFMANMILLERWOLDOWESCHERLIKARNOFSKYBURCHENAL CWRRRDSNREIGMCDAJH: The clinical evaluation of 5-fluorouracil and 5-fluoro-2-deoxyuridine in solid tumors in adults: a progressive report. Cancer Chemother. Rep. 6: 17, 1960. MedlineGoogle Scholar13. ANSFIELDCURRERI FJAR: Clinical studies with 5-fluoro-2-deoxyuridine. Cancer Chemother. Rep. 6: 21, 1960. MedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: HORACE K. IVY, M.D.Affiliations: Rochester, MinnesotaFrom the Section of Medicine, Mayo Clinic and Mayo Foundation, Rochester, Minnesota.Requests for reprints should be addressed to Mayo Clinic, Rochester, Minnesota. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byDevelopment of a photoresponsive chitosan conjugated prodrug nano-carrier for controlled delivery of antitumor drug 5-fluorouracilThe Beginnings of Medical Oncology at the Mayo Clinic in RochesterThe Beginnings of Medical Oncology at the Mayo Clinic in RochesterTherapeutic consequences of antitumour drug interactions: Methotrexate and 5-fluorouracil in the chemotherapy of C3H mice with transplanted mammary adenocarcinomaCicatricial ectropion secondary to 5-fluorouracil therapySystemic chemotherapy for advanced breast cancer3 Some Pyrimidines of Biological and Medicinal Interest—I5-FLUOROURACILManagement of Metastatic Lesions of BoneÜber neue ArzneimittelCombined Hormonal and Cytotoxic Treatment of Advanced Breast Cancer. 1 October 1962Volume 57, Issue 4Page: 598-605KeywordsBreast cancerCancer chemotherapyCancer treatmentChemotherapeutic agentsChemotherapyNucleic acidsToxicity ePublished: 1 December 2008 Issue Published: 1 October 1962 PDF downloadLoading ...